Pharma's Market
SPECIAL REPORT
MOST SHARED
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- US Hedge Fund Manager Charged with Insider Trading
- Anthony Scaramucci: S&P 500 Stocks Still Cheap
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- Investing in the Fountain of Youth
- Verizon, Coinstar Team Up to Take on Netflix
- We Are Well Positioned for 2012: CEO Alcatel Lucent
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- CEO to CEO: Our Roles Are Changing
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Greece Austerity Deal Runs Into Trouble Once Again
- Why Greece Will Default, Leave Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
- Private Homebuilders: Dead Men Walking
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Diamond Investing: Why It's Not for the Faint of Heart
RSS FEED
Pfizer's Chantix Warning: Hazardous To Mental Health?
Text Size 
Reporter
 |
] announced this morning that it is putting a warning--and that's the company's word--on the label of its stop-smoking pill Chantix. It says people taking the drug should be watched for "serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior." But PFE is quick to point out that, "A causal relationship between CHANTIX and these reported symptoms has not been established. In some reports, however, an association could not be excluded." You can read the full press release here.
As I blogged earlier this week, Chantix is a growth driver at Pfizer. The world's biggest drug company reports earnings next Wednesday morning with a conference call at noon EST.
Look in the earnings press release to see what happened to Chantix sales in the fourth quarter when the reports of psychiatric side effects from Chantix reached critical mass. An analyst says since the first of the year, though, Chantix prescriptions appear to have rebounded to earlier levels, but it's too early to tell if that's a New Year's resolution effect.
While the formal warning is not unexpected, a side effect issue with a successful new drug is not what the doctor ordered for the pipeline- and shareholder-value-challenged PFE.
The question is whether smokers' desire to quit will outweigh their fear of serious psychiatric side effects.
Pfizer says more than four million people in the U.S. have gotten a prescription for Chantix since it came to market in May 2006.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
